Sutro Biopharma Operating Expenses Growth & History (STRO)
Sutro Biopharma's operating expenses was $260.9M for fiscal 2025.
View full Sutro Biopharma company overviewSutro Biopharma annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $260.9M | −$39.6M | −13.19% |
| 2024 | 2024-12-31 | $300.5M | $57.5M | +23.66% |
| 2023 | 2023-12-31 | $243.0M | $46.3M | +23.53% |
| 2022 | 2022-12-31 | $196.7M | $36.3M | +22.64% |
| 2021 | 2021-12-31 | $160.4M | $46.6M | +40.98% |
| 2020 | 2020-12-31 | $113.8M | $15.6M | +15.86% |
| 2019 | 2019-12-31 | $98.2M | $22.6M | +29.83% |
| 2018 | 2018-12-31 | $75.6M | $4.6M | +6.52% |
| 2017 | 2017-12-31 | $71.0M | $12.6M | +21.67% |
| 2016 | 2016-12-31 | $58.4M | — | — |
Sutro Biopharma quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $39.7M | −$27.4M | −40.79% |
| Q1 2026 | 2026-03-31 | $44.2M | −$41.7M | −48.58% |
| Q4 2025 | 2025-12-31 | $49.7M | −$30.4M | −37.93% |
| Q3 2025 | 2025-09-30 | $58.2M | −$18.3M | −23.92% |
| Q2 2025 | 2025-06-30 | $67.1M | −$7.3M | −9.81% |
| Q1 2025 | 2025-03-31 | $85.9M | $16.3M | +23.44% |
| Q4 2024 | 2024-12-31 | $80.1M | $9.5M | +13.46% |
| Q3 2024 | 2024-09-30 | $76.4M | $15.5M | +25.44% |
| Q2 2024 | 2024-06-30 | $74.4M | $17.8M | +31.45% |
| Q1 2024 | 2024-03-31 | $69.6M | $14.7M | +26.75% |
| Q4 2023 | 2023-12-31 | $70.6M | $12.7M | +21.98% |
| Q3 2023 | 2023-09-30 | $60.9M | $14.6M | +31.45% |
| Q2 2023 | 2023-06-30 | $56.6M | $9.1M | +19.20% |
| Q1 2023 | 2023-03-31 | $54.9M | $9.9M | +21.95% |
| Q4 2022 | 2022-12-31 | $57.9M | $12.2M | +26.62% |
| Q3 2022 | 2022-09-30 | $46.4M | $3.2M | +7.33% |
| Q2 2022 | 2022-06-30 | $47.5M | $9.6M | +25.42% |
| Q1 2022 | 2022-03-31 | $45.0M | $11.4M | +33.74% |
| Q4 2021 | 2021-12-31 | $45.7M | $12.6M | +37.95% |
| Q3 2021 | 2021-09-30 | $43.2M | $14.8M | +51.87% |
| Q2 2021 | 2021-06-30 | $37.9M | $12.0M | +46.23% |
| Q1 2021 | 2021-03-31 | $33.7M | $7.3M | +27.86% |
| Q4 2020 | 2020-12-31 | $33.1M | $7.0M | +26.96% |
| Q3 2020 | 2020-09-30 | $28.4M | $3.4M | +13.71% |
| Q2 2020 | 2020-06-30 | $25.9M | $1.7M | +6.92% |
| Q1 2020 | 2020-03-31 | $26.3M | $3.4M | +15.01% |
| Q4 2019 | 2019-12-31 | $26.1M | $3.7M | +16.66% |
| Q3 2019 | 2019-09-30 | $25.0M | $7.0M | +39.01% |
| Q2 2019 | 2019-06-30 | $24.2M | $6.4M | +36.07% |
| Q1 2019 | 2019-03-31 | $22.9M | $5.4M | +30.86% |
| Q4 2018 | 2018-12-31 | $22.4M | — | — |
| Q3 2018 | 2018-09-30 | $18.0M | −$571,000 | −3.08% |
| Q2 2018 | 2018-06-30 | $17.8M | — | — |
| Q1 2018 | 2018-03-31 | $17.5M | — | — |
| Q3 2017 | 2017-09-30 | $18.6M | — | — |
Sutro Biopharma operating expenses trends
Over the last five fiscal years, Sutro Biopharma's operating expenses increased from $113.8M to $260.9M, a change of $147.1M. The latest reported quarter, Q2 2026, shows $39.7M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sutro Biopharma source filings ↗